Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.

Leukemia - 1 Sept 2024

Ernst Philipp, Rinke Jenny, Franke Georg-Nikolaus, Dicker Frank, Haferlach Torsten, Ernst Thomas, Hochhaus Andreas

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to ABL1 gene
Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Niacinamide

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 38965368
DOI: 10.1038/s41375-024-02327-2
PMCID: PMC11347363

Genes

ABL1
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.PMID 38965368Read ↗

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.Semantic proximity Read ↗

A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.Semantic proximity Read ↗

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.Semantic proximity Read ↗

Asciminib in chronic myeloid leukemia.Semantic proximity Read ↗

Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free RemissionSemantic proximity Read ↗

Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemiaSemantic proximity Read ↗

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.Semantic proximity Read ↗

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.Semantic proximity Read ↗

Asciminib in the treatment of chronic myeloid leukemia in chronic phase.Semantic proximity Read ↗

In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.Semantic proximity Read ↗

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.Semantic proximity Read ↗

Asciminib for chronic myeloid leukaemia: Next questions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.